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Abstract
Purpose The primary aim of this trial was to assess the
rate of pathologic complete responses (pCR) of doxor-
ubicin/cyclophosphamide (AC) followed by bevacizumab/
docetaxel (BT), as neoadjuvant therapy for breast cancer
(BC). Furthermore, the association between biomarkers
and the pCR was explored.
Methods Patients with HER-negative operable stage II–III
BC C2 cm were enrolled. Four cycles of AC (A 60 mg/m2
and C 600 mg/m2, every 3 weeks) followed by 4 cycles of
BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were
planned. A core-biopsy was performed for biological
markers assessment.
Results Seventy-two women were included. Forty-three
(63 %) patients were hormone receptor-positive. Sixty-four
(89 %) completed the planned treatment, and 66 evaluable
patients underwent surgery (92 %): a pCR was achieved in
16 of them (24, 95 % CI 15–36 %). pCR was significantly
higher in tumors hormone receptor-negative, and in those
with Angiotensin II type 1 receptor (AGTR1) protein
overexpression. The overall clinical response rate was
86 % (95 % CI 76–93 %), including 42 complete respon-
ses. No unexpected toxicities or treatment-related deaths
were observed.
Conclusion This regimen showed a remarkable clinical
and pathological activity: the suggested relation between
pCR and AGTR1 overexpression should be confirmed in
larger trials.
Keywords Bevacizumab  Biomarkers  Breast cancer 
Combined modality therapy  Neoadjuvant therapy
Introduction
It has been suggested that the pathological response of the
tumor and the number of affected lymph nodes are the most
important prognostic factors in terms of prolonging sur-
vival after neoadjuvant chemotherapy [1, 2].
The combination of docetaxel with anthracyclines rep-
resents one of the standards in the primary treatment of
breast cancer (BC) [3].
Numerous studies have demonstrated that therapeutic
disruption of nascent vasculature is effective in mediating
tumor regression [4]. The anti-angiogenic agent bev-
acizumab (Avastin; Genentech Inc., San Francisco, CA,
USA; Hoffmann-La Roche Ltd, Basel, Switzerland) is a
humanized monoclonal antibody with binding specificity
for vascular endothelial growth factor (VEGF): it has the
potential to decrease the size of a tumor by reducing its
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blood supply and enhancing the activity of cytotoxic
therapies.
The addition of a drug with a biological mode of action,
such as bevacizumab, to a docetaxel-based cytotoxic reg-
imen may increase the antitumor activity and prognosis of
women with BC without increasing the treatment toxicity.
Indeed, there is evidence from in vitro studies suggesting
that docetaxel has antiangiogenic effects which increase
synergistically with bevacizumab administration [5].
Neoadjuvant therapy has been used to assess the rele-
vance of biological markers as potential predictive factors
for efficacy. C-erbB2, p53, Ki-67 labeling index, VEGFR,
and hormone receptor (HR) status, among others, has been
evaluated as predictive markers in several trials, with
contradictory or inconclusive results [6–14]. Therefore, this
issue remains unsolved, being of special relevance in
antiangiogenic combination treatments.
The present multicenter, open-label, phase II study was
designed to evaluate the efficacy and the safety profile of a
sequential treatment with the classical regimen of doxor-
ubicin/cyclophosphamide (AC) followed by the combina-
tion of bevacizumab plus docetaxel (BT) in the neo-
adjuvant treatment of operable BC, as well as the possible
correlation between the expression of certain biomarkers
and the efficacy of this therapeutic approach.
Patients and methods
Eligibility criteria
The primary objective was to assess the efficacy, measured
as the rate of pathologic complete responses (pCR) at
surgery after receiving sequential induction chemotherapy
with AC followed by BT. Secondary objectives included
the assessment of the objective response rate (ORR) and
safety profile of the regimen, the percentage of breast-
conserving surgery, and the study of the potential associ-
ation between several recognized biomarkers in the base-
line biopsy and the pathological response to the study
treatment.
The study was performed after approval by the Inde-
pendent Ethics Committee of each site and in accordance
with the Declaration of Helsinki, the Good Clinical Prac-
tices, and local ethical and legal requirements. Before study
entry all patients provided written informed consent
according to local ethical committee regulations. A specific
informed consent was asked to patients to provide a tumor
sample to be analyzed for biomarkers: it was not manda-
tory to accept this proposal to be included in the study.
Patients with histological or cytological confirmed
operable stage II–III BC C2 cm, HER2-negative, without
prior treatment for BC, were enrolled at 6 sites in Spain.
Other inclusion criteria included: Eastern Cooperative
Oncology Group (ECOG) performance status (PS) B1,
adequate hepatic, renal, and bone marrow function, and a
left ventricular ejection fraction (LVEF) C55 %. Patients
were excluded from participation if they had other
comorbidity conditions including neuropathy [grade 2
according to National Cancer Institute-Common Termi-
nology Criteria for Adverse Events (NCI-CTCAE), and
clinically significant cardiac disease (New York Heart
Association, Class CII). In addition, patients with a prior
history of bleeding or coagulopathy with risk of bleeding,
and current use of full dose or parenteral anticoagulants or
chronic daily treatment with aspirin (\325 mg/day) also
were excluded.
Treatment schedule
Patients should receive four cycles of AC regimen (doxo-
rubicin at 60 mg/m2 iv bolus over 15 min plus cyclo-
phosphamide at 600 mg/m2 iv infusion over 5–60 min at
day 1 every 3 weeks) followed by four cycles of BT reg-
imen (bevacizumab at 15 mg/kg iv infusion followed by
docetaxel at 75 mg/m2/day iv at day 1 every 3 weeks).
Patients were scheduled to undergo surgery at least
4 weeks after receiving the last bevacizumab and/or
docetaxel dose. Breast-conserving surgery was done
whenever possible (diameter \2 cm, absence of central
localization and disseminated calcifications).
Study assessments
Before study entry, all patients were evaluated for their
axillary nodes and breast disease, including a complete
anamnesis and physical examination, a radiological
examination using mammography, ultrasonography and/or
magnetic resonance imaging (MRI) of the breast, a routine
blood analysis (hematology and biochemistry), an assess-
ment of the ECOG PS and a measurement of the LVEF. In
addition, chest radiography and computed tomography
(CT) of the chest and abdomen, as well as bone scintig-
raphy were performed within 28 days before the start of the
study treatment to exclude the presence of metastases.
Performance status and vital sign assessments, routine
blood analysis and urinalysis were repeated before each
treatment cycle until final follow-up visit, which occurred
12 months after treatment. LVEF was repeated before first
BT infusion and after surgery.
Patients underwent a core-biopsy of the primary tumor
for the diagnosis and the biological characterization of the
tumor, including HR and HER-2 status in all patients, and
Ki-67 labeling index (low if \15 % and high if C15 %),
and other biological markers (VEGF, VEGFR, PAKT,
PMAPK, KISS1, RKISS1, HIF, eNOS, AGTR1, and IGF)
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in those who give their consent to have the biomarkers
analyzed. The protocol for collection and measurement of
these markers has been described previously [10].
Tumor evaluation was indicated after each cycle by
physical exploration, and every 4 cycles (after AC regimen,
and then after completion of BT cycles) by breast MRI
and/or ultrasonography. RECIST v.1.0 response guidelines
were used [15] to define tumor responses: imaging-based
evaluation was always being done rather than physical
examination unless the lesion(s) being followed could not
be imaged but was assessable by clinical exam.
An anatomopathological evaluation of the surgical
sample was done after surgery, as well as an assessment of
the same biological markers obtained at the basal core-
biopsy. An absence of invasive tumor cells within the
breast and lymph nodes was classified as a pCR, according
to the Miller and Payne criteria [16].
Toxicity was evaluated at the initiation of each cycle
and until 28 days after the last study drug dose adminis-
tration, using the NCI-CTCAE version 3.0.
Statistical considerations
A Simon two-stage design [17] was used to calculate the
required sample size, based on testing a null hypothesis H0
pCR rate B20 % and an alternative hypothesis H1 pCR rate
C35 %, with an alpha level of 0.05 and a statistical power
of 80 % (beta error = 0.20). Seventy-two evaluable
patients were required to achieve these goals. The study
would be stopped if B5 pCR resulted after evaluation of 22
patients.
The primary efficacy analysis for clinical response was
performed on the intention to treat (ITT) population,
defined as all included patients. Population assessable to
clinical response included patients with no major protocol
violations, who had received at least 2 cycles of treatment
(those with early progression after first cycle were also
included) and with a tumor evaluation after those 2 cycles.
To be assessable to pathological response, patients should
have received at least 2 cycles of treatment, and have had
their tumor anatomopathologically analyzed, without major
protocol violations. Safety population comprised all
included patients who received at least one administration
of any study drug.
Frequency and percentage of pCR and ORR, together
with the IC 95 %, were presented. The association between
baseline characteristics, including biomarkers, and patho-
logical/clinical response was evaluated by logistic regres-
sion in both univariate and multivariate analyses. All
p values were two-sided with a significance level of 0.05.
The statistical analyses were run using SAS version 9.2.
The guidelines for the reporting of tumor marker studies




A total of seventy-two women from six Spanish centers
were enrolled from December 2007 to March 2009. Fig-
ure 1 details patient disposition and Table 1 presents the
Fig. 1 Disposition of patients. a Two
patients were excluded because of
major protocol violation (HER2 3?).
b One patient was excluded because of
major protocol violation (HER2 3?)
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basal characteristics of the patients. All but one woman had
an ECOG PS of 0. Median tumor size (physical examina-
tion) was 5 cm (range 2–15). Forty-three patients (60 %)
had tumors that were estrogen (ER) and progesterone
receptor (PgR) positive.
Treatment compliance
Sixty-four patients (89 %) completed the planned treat-
ment (4 cycles of AC ? 4 cycles of BT ? surgery). AC
was administered for four courses in 70 patients, and dis-
continued after the second cycle because of progression in
one patient, and after the third cycle in another due to
major protocol deviation (HER2-positive). BT was not
administered to 2 patients because of consent withdrawal;
four patients did not complete the planned 4 cycles of BT
because of hypersensitivity reactions to docetaxel (1
patient after the first BT cycle, 2 after the second cycle, and
1 after the third cycle); one patient did not receive bev-
acizumab on cycles 3 and 4 due to uncontrolled
hypertension.
A total of 286 cycles of AC were delivered. Adminis-
tration was delayed in 53 cycles (37 patients), mostly
(64 % of delays) due to causes not related to the treatment
(organizational problems at the study center such as holi-
days, agenda adjustments or delay in the results of diag-
nostic tests): in 30 % of cases the delay was due to
hematologic toxicity. The dose of doxorubicin was reduced
in 4 cycles, due to hematologic toxicity, and the dose of
cyclophosphamide in 1 cycle (non-hematologic toxicity).
Bevacizumab ? docetaxel was administered to 68 patients
Table 2 Maximum toxicity
(any grade 3/4 toxicity) per
patient according to NCI-CTC
criteria v3.0 (N = 72)




neutrophil count \1.0 9 109/L,
fever C38.5 C)
Grade 1/2 Grade 1/2 (%) Grade 3/4 Grade 3/4 (%)
Hematological toxicity
Neutropenia 7 10 8 11
Febrile neutropeniaa 1 1 8 11
Non-hematological toxicity
Mucositis 31 43 14 19
Nausea 36 50 7 10
Vomiting 20 28 5 7
Fatigue 39 54 5 7
Allergic reaction/hypersensitivity 10 14 4 6
Diarrhea 15 21 2 3
Alopecia 35 49 1 1
Pain 35 49 1 1
Fever (without neutropenia) 13 18 1 1
Nail changes 11 15 1 1
Hypertension 6 8 1 1
Table 1 Patient characteristics













Infiltrating ductal carcinoma 69 96
Infiltrating lobular carcinoma 2 3












ER estrogen receptor, PgR progesterone receptor
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(264 cycles), and 46 cycles (35 patients) were delayed, in
78 % of them due to causes not related to the treatment
(organizational problems at the study center), and in 15 %
due to hematologic toxicity. Dose of docetaxel was reduced
in 15 cycles (12 patients), mainly due to non-hematologic
toxicity (10 cycles). Per protocol, there were no adjust-
ments in the dose of bevacizumab.
Safety
All patients were evaluable for safety. There were no
surgical complications. The maximum toxicity per patient
grade 3/4, irrespective of relationship to study treatment, is
summarized in Table 2. Eleven patients presented 13
severe AEs classified as probably related to any study
medication: 6 cases of febrile neutropenia (4 patients grade
3 and 2 patients grade 4), 4 of neutropenia (1 patient grade
3 and 3 patients grade 4), 2 of grade 3 mucositis, and 1 case
of grade 3 vomiting. Cardiac dysfunction with heart failure
symptoms was not observed. No patient died of treatment
toxicity.
Efficacy
Sixty-seven patients underwent surgery, being performed
breast-conserving surgery in 42 of them (63, 95 % CI
50–74).
Four patients did not undergo surgery due to consent
withdrawal (2 patients), disease progression (1 patient), and
toxicity (1 patient). One patient was excluded from the
pathological response assessable population due to major
protocol deviation (HER2-positive). A total of 16/66
patients (24, 95 % CI 15–36 %) achieved pCR. No asso-
ciation was observed between pCR and age or tumor size
(B2 vs. [2 cm). A statistically significant association
(p = 0.0094) was founded between the rate of pCR and the
HR status (pCR rate of 54 and 17 % in HR- and HR?
patients, respectively) (Table 3).
In the ITT population analysis, a clinical ORR of 89 %
(95 % CI 79–95 %) was documented (64/72 included
patients), with 42 patients reaching complete response
(CR) (58, 95 % CI 46–70 %). Six patients had stable dis-
ease (8 %), and 1 patient had disease progression after
receiving 2 cycles of AC.
Study of other potentially predictive factors
Forty-nine patients gave their consent to have the bio-
markers analyzed. Table 3 shows pCR rates relative to the
explored biological markers in the baseline biopsy, as well
as the number of analyzed cases: in some tumor samples,
not all biomarkers could be studied due to suboptimal
quality of biopsy.
Table 3 Pathological response rate according to biological markers
analysis




- 13 7 (54)
? 54 9 (17)
Ki-67 0.3275
- 7 0 (0)
? 47 12 (26)
Biomarkers amplification
KISS1 23 0.4864
Aneuploid 8 1 (13)
Normal 13 4 (31)
Amplification 2 1 (50)
VEGFR 23 0.3401
Aneuploid 1 0 (0)
Normal 18 6 (33)
Amplification 4 0 (0)
Biomarkers protein expression
KISS1 25 0.6016
Normal 21 7 (33)
Overexpressed 4 2 (50)
VEGFR 22 0.6462
Normal 12 4 (33)
Overexpressed 10 2 (20)
HIF 38 0.3367
Normal 33 11 (33)
Overexpressed 5 3 (60)
eNOS 38 1.000
Normal 34 11 (33)
Overexpressed 4 1 (25)
AGTR1 26 0.0033
Normal 15 1 (7)
Overexpressed 11 7 (64)
Biomarkers gene expression
VEGF 34 0.3235
Higher 1 1 (100)
Lower 33 10 (30)
VEGFR 34 0.0693
Higher 7 0 (0)
Lower 27 11 (41)
HIF 34 0.4254
Higher 9 4 (44)
Lower 25 7 (28)
eNOS 34 1.000
Higher 1 0 (0)
Lower 33 11 (33)
KISS1 34 1.0000
Higher 1 0 (0)
Lower 33 11 (33)
Italic values indicate p-value \0.05
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A statistical significant association was observed
between Angiotensin II type 1 receptor (AGTR1) protein
overexpression and pCR (p = 0.0033). No other biomarker
significantly correlated with pCR.
Using a non parametric test (Wilcoxon Mann–Whitney)
to compare eNOS data expression as continuous variable
between patients with pCR and non pCR, an association
between higher levels of eNOS and probability of reaching
pCR was found (p = 0.07 bilateral test, and p = 0.03
unilateral test).
An analysis cluster was made with those patients with
assessable anatomopathological response in whom Ki67,
AGTR, ENOS, VGFR, ER, and PgR were evaluated (16
patients). That analysis showed that three clusters (ER/
PgR, ENOS/VEGFR, and Ki67/AGTR) explained 80 % of
the variability of the anatomopathological response. A
graphical representation of that relation is shown in Fig. 2.
Discussion
HER2 overexpression and HR-status are associated with
substantially higher pCR rates [19–25]. In our study, one of
the largest published phase II study testing bevacizumab as
neoadjuvant treatment of BC, all included patients had
HER2-negative disease and 43 (60 %) were HR?: more-
over, the median tumor size (physical examination) was
high (5 cm). In spite of these unfavorable prognostic fea-
tures, the reached 24 % pCR rate falls within the range
reported for anthracycline and taxane-containing regimens
in populations unselected for HER2 status [3, 26–28], as
well as of that reported for others with bevacizumab plus
chemotherapy [7–9]. It was noteworthy that the 17 % (9/54
patients) pCR rate reached in the subgroup of women with
HR? disease, in line with results of the NSABP B40 study
[13], where the effect of adding bevacizumab to neoadju-
vant chemotherapy was predominantly in the HR? subset,
although without reach statistic significance. Moreover,
recently published data from the GeparQuinto study [14],
suggest that the effect of the addition of bevacizumab to
EC-docetaxel chemotherapy on pCR rates derived mainly
from patients with triple-negative BC: nevertheless, the test
for interaction was not significant (p = 0.07) in this study,
which was not powered to show these differential effects.
Randomized studies designed to address the efficacy of
bevacizumab in tailored populations are needed to clarify
these points.
Regarding clinical responses, our 89 % ORR (ITT
population) is among the highest reported in other similar
neoadjuvant trials with bevacizumab-based combinations
(67–87 % ORR) [6, 8, 9, 11, 29, 30]. Even taking into
account that a comparison with previous phase II studies
can be only speculative, it was noteworthy that 42 out of 72
patients (58 %) reached a clinical CR, which compares
very favorably with that achieved by others [8, 29, 30].
Interestingly, 17/24 non responding patients after AC
obtained a further partial or CR to BT. Moreover, 19 out of
33 improved their partial responses to complete responses
at the end of BT treatment, suggesting that a significant
proportion of clinical and pathological responses may be
attributable to the combination of bevacizumab plus
docetaxel. These results allowed a remarkable 63 % breast-
conserving surgery rate (42/72 patients).
The regimen was very well tolerated, in line with other
previously published regimens with bevacizumab as pri-
mary treatment of breast cancer [6, 8, 9, 11, 29, 30], with a
Fig. 2 Cluster analysis of
relation between
anatomopathological response
and biomarkers and hormonal
receptor status (subset of
patients with assessable
anatomopathological response
and informed biomarkers and
hormonal receptors: N = 16)
Green color, expressed
biomarker or high proliferative
index of Ki67; red color, not
expressed biomarker or low
proliferative index of Ki67;
yellow color, negative hormone
receptor; black color, positive
hormone receptor. Cluster 1,
ER/PgR; Cluster 2, ENOS/
VEGFR; Cluster 3, Ki67/AGTR
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high proportion of patients (89 %) receiving all treatment
as planned. The incidence of grade 3/4 hematological and
non-hematological toxicities was low, with only 11/72
patients presenting any AE classified as probably related to
any study medication. No toxic death was found and only
one patient did not receive bevacizumab for 2 cycles due to
uncontrolled hypertension.
This study also evaluated some biological markers as
predictors for pCR. In our understanding, this is the first
clinical study that suggests that Angiotensin II type 1
receptor (AGTR1) protein overexpression may be related
to the pCR to bevacizumab treatment in BC patients. In
a similar way, the association between higher levels of
eNOS and probability of reaching pCR found in our
study should be corroborated in larger studies specifically
aimed to address this issue. No statistical correlation
between any other studied biomarker and the pathologi-
cal outcome has been found, probably due to the small
number of subjects in each subgroup. In particular, no
statistically significant association was found between the
proliferation-related levels of Ki67 and the pCR rate,
although no pCR was reached in any patient with low
Ki67 levels. In a previous study [10], we found a rela-
tion between Ki67 positive tumors and pCR; neverthe-
less, in other similar phase II studies with bevacizumab
[8, 11, 12] this correlation did not reach a statistical
signification. Further studies on a larger number of
patients are therefore required to evaluate the role of
these biomarkers.
In conclusion, the high rate of clinical and pathological
activity and low incidence of severe toxicity seen with the
addition of bevacizumab to this standard sequential sche-
dule of neoadjuvant chemotherapy, even in a population of
patients with adverse prognostic factors, suggests that this
regimen can be used in randomized trials to address fun-
damental clinical questions about patient-tailored regi-
mens, timing and duration of bevacizumab therapy. In
particular, the identification of reliable biomarkers that
predict response or resistance to antiangiogenic treatments
and can be used for the selection of patients eligible for
therapy with bevacizumab remains a priority. Those strat-
egies would help to individualize more efficiently primary
systemic therapy for patients with breast cancer.
Acknowledgments Financial support for this research was provided
by Roche Farma, S.A.
Conflict of interest The authors have declared no conflicts of
interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Ellis P, Smith I, Ashley S et al (1998) Clinical prognostic and predictive factors
for primary chemotherapy in operable breast cancer. J Clin Oncol
16(1):107–114
2. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemo-
therapy on the outcome of women with operable breast cancer. J Clin Oncol
16(8):2672–2685
3. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or post-
operative docetaxel added to preoperative doxorubicin plus cyclophosphamide
for operable breast cancer: National Surgical Adjuvant Breast and Bowel Pro-
ject Protocol B-27. J Clin Oncol 24(13):2019–2027
4. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature
438(7070):967–974
5. Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of
docetaxel is synergistic with a recombinant humanized monoclonal antibody
against vascular endothelial growth factor or 2-methoxyestradiol but antago-
nized by endothelial growth factors. Cancer Res 61(8):3369–3372
6. Baar J, Silverman P, Lyons J et al (2009) A vasculature-targeting regimen of
preoperative docetaxel with or without bevacizumab for locally advanced breast
cancer: impact on angiogenic biomarkers. Clin Cancer Res 15(10):3583–3590
7. Bahri S, Chen JH, Mehta RS et al (2009) Residual breast cancer diagnosed by
MRI in patients receiving neoadjuvant chemotherapy with and without bev-
acizumab. Ann Surg Oncol 16(6):1619–1628
8. Balduzzi A, Montagna E, Bagnardi V et al (2009) Infusional fluorouracil,
epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in
locally advanced breast cancer with unfavorable prognostic features. Anticancer
Drugs 20(3):197–203
9. Greil R, Moik M, Reitsamer R et al (2009) Neoadjuvant bevacizumab, doce-
taxel and capecitabine combination therapy for HER2/neu-negative invasive
breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol
35(10):1048–1054
10. Sanchez-Munoz A, Duenas-Garcia R, Jaen-Morago A et al (2010) Is it possible
to increase pCR in the neoadjuvant treatment with a dose-dense/sequential
combination?: results from a phase II Trial combining epirubicin and cyclo-
phosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II
and III breast cancer patients. Am J Clin Oncol 33(5):432–437
11. Torrisi R, Bagnardi V, Cardillo A et al (2008) Preoperative bevacizumab
combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-
positive breast cancer: clinical and biological activity. Br J Cancer
99(10):1564–1571
12. Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM (2008)
Gene expression profile and angiogenic marker correlates with response to
neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in
breast cancer. Clin Cancer Res 14(18):5893–5899
13. Bear HD, Tang G, Rastogi P et al (2012) Bevacizumab added to neoadjuvant
chemotherapy for breast cancer. N Engl J Med 366(4):310–320
14. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemo-
therapy and bevacizumab for HER2-negative breast cancer. N Engl J Med
366(4):299–309
15. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate
the response to treatment in solid tumors. European Organization for Research
and Treatment of Cancer, National Cancer Institute of the United States,
National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
16. Smith IC, Miller ID (2001) Issues involved in research into the neoadjuvant
treatment of breast cancer. Anticancer Drugs 12(Suppl 1):S25–S29
17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control
Clin Trials 10(1):1–10
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005)
Reporting recommendations for tumor marker prognostic studies (REMARK).
J Natl Cancer Inst 97(16):1180–1184
19. Colleoni M, Viale G, Zahrieh D et al (2008) Expression of ER, PgR, HER1,
HER2, and response: a study of preoperative chemotherapy. Ann Oncol
19(3):465–472
20. Fernandez-Morales LA, Segui MA, Andreu X et al (2007) Analysis of the
pathologic response to primary chemotherapy in patients with locally advanced
breast cancer grouped according to estrogen receptor, progesterone receptor, and
HER2 status. Clin Breast Cancer 7(7):559–564
21. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic
complete response after primary chemotherapy in relation to hormone receptor
status and other factors. J Clin Oncol 24(7):1037–1044
22. Keam B, Im SA, Kim HJ et al (2007) Prognostic impact of clinicopathologic
parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and
doxorubicin chemotherapy: paradoxical features of the triple negative breast
cancer. BMC Cancer 7:203
23. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy
and long-term survival in patients with triple-negative breast cancer. J Clin
Oncol 26(8):1275–1281
24. Mehta RS (2008) Hormone receptor, grade, human epidermal growth factor
receptor 2, and topoisomerase II as predictors of response to chemotherapy.
J Clin Oncol 26(15):2596–2597
816 Clin Transl Oncol (2013) 15:810–817
123
25. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular
subtypes respond differently to preoperative chemotherapy. Clin Cancer Res
11(16):5678–5685
26. Evans TR, Yellowlees A, Foster E et al (2005) Phase III randomized trial of
doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as pri-
mary medical therapy in women with breast cancer: an anglo-celtic cooperative
oncology group study. J Clin Oncol 23(13):2988–2995
27. Heys SD, Hutcheon AW, Sarkar TK et al (2002) Neoadjuvant docetaxel in
breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast
Cancer 3(Suppl 2):S69–S74
28. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclo-
phosphamide followed by docetaxel every 21 days compared with doxorubicin
and docetaxel every 14 days as preoperative treatment in operable breast cancer:
the GEPARDUO study of the German Breast Group. J Clin Oncol
23(12):2676–2685
29. Forero-Torres A, Saleh MN, Galleshaw JA et al (2010) Pilot trial of preoper-
ative (neoadjuvant) letrozole in combination with bevacizumab in postmeno-
pausal women with newly diagnosed estrogen receptor- or progesterone
receptor-positive breast cancer. Clin Breast Cancer 10(4):275–280
30. Wedam SB, Low JA, Yang SX et al (2006) Antiangiogenic and antitumor
effects of bevacizumab in patients with inflammatory and locally advanced
breast cancer. J Clin Oncol 24(5):769–777
Clin Transl Oncol (2013) 15:810–817 817
123
